NL
DE
News items
Vici grant
23 February 2018
Maroeska Rovers is Professor of Evidence-based Surgery at Radboud university medical center, within the theme of Urological cancers. It is her ambition to contribute to the development of effective, affordable, and valuable surgical innovations.
Rovers will use her Vici grant to perform research with the aim of developing better methods to evaluate surgical innovations as early as possible. Currently, this evaluation takes place when these innovations have largely been developed and marketed. Up to half of the innovations do not add any value which results in a waste of healthcare costs in Europe. According to Rovers, new medical tools should already be evaluated for added value for patients as early as the very first concept. She intends to develop, test, and validate methods for this.
Maroeska Rovers, Professor of Evidence Based Surgery, will receive a Vici research grant of 1.5 million euros from NWO (Netherlands Organisation for Scientific Research).
Maroeska Rovers is Professor of Evidence-based Surgery at Radboud university medical center, within the theme of Urological cancers. It is her ambition to contribute to the development of effective, affordable, and valuable surgical innovations.
Rovers will use her Vici grant to perform research with the aim of developing better methods to evaluate surgical innovations as early as possible. Currently, this evaluation takes place when these innovations have largely been developed and marketed. Up to half of the innovations do not add any value which results in a waste of healthcare costs in Europe. According to Rovers, new medical tools should already be evaluated for added value for patients as early as the very first concept. She intends to develop, test, and validate methods for this.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Liver tumors irradiated from inside can be followed live from outside
17 February 2022 A Dutch research team from Radboud University Medical Center has visualized the injection of radioactive microspheres during treatment of a patient with liver tumors ‘live on screen’. read more
LUMO Labs and Oost NL invest in Aiosyn Investment accelerates development of artificial intelligence platform to improve diagnostics
7 February 2022 Aiosyn, a spin-off from Radboudumc, has received an investment from LUMO Labs. Oost NL is a co-investor. read more
Body composition is more important than BMI for renal cancer survival rates
11 January 2022 Body composition is important for survival rates in renal cell cancer. Research from the Radboudumc shows that low muscle quality and low organ fat are associated with poor survival. This involves different stages of renal cancer, ranging from stage I-III to stage IV. read more
Large AI project receives over €95 million for ten years of public-private research
23 September 2021 The Dutch Research Council (NWO) is to fund two consortia for a period of ten years. Radboudumc participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboudumc leads five of these eight labs. read moreNew start-up Patholyt will bring AI research into pathology diagnostics
21 September 2021 Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research. read more